Article (Published version) (1.3 MB) - 
Free access
Highlights
Scientific Article - Review
unige:132571 
 |
ILC2s: new actors in tumor immunity |
|
| Authors | ||
| Published in | Frontiers in immunology. 2019, vol. 10, 2801 | |
| Abstract | Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies. | |
| Identifiers | PMID: 31849977 | |
| Full text | ||
| Research group | Ciblage des lymphocytes sécrétant des cytokines (1015) | |
| Projects | Swiss National Science Foundation: PZ00P3_161459 Swiss National Science Foundation: PR00P3_179727 | |
| Citation (ISO format) | ERCOLANO, Giuseppe et al. ILC2s: new actors in tumor immunity. In: Frontiers in Immunology, 2019, vol. 10, p. 2801. doi: 10.3389/fimmu.2019.02801 https://archive-ouverte.unige.ch/unige:132571 |
212 hits 
68 downloads 
Contact an author
Update